- Home
- BMEA vs ATOM Comparison
BMEA vs ATOM Comparison
Compare BMEA & ATOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- ATOM
- Stock Information
- Founded
- BMEA 2017
- ATOM 2001
- Country
- BMEA United States
- ATOM United States
- Employees
- BMEA 63
- ATOM N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- ATOM Semiconductors
- Sector
- BMEA Health Care
- ATOM Technology
- Exchange
- BMEA Nasdaq
- ATOM Nasdaq
- Market Cap
- BMEA 96.9M
- ATOM 142.0M
- IPO Year
- BMEA 2021
- ATOM 2016
- Fundamental
- Price
- BMEA $1.36
- ATOM $2.70
- Analyst Decision
- BMEA Strong Buy
- ATOM
- Analyst Count
- BMEA 7
- ATOM 0
- Target Price
- BMEA $8.86
- ATOM N/A
- AVG Volume (30 Days)
- BMEA 1.7M
- ATOM 763.2K
- Earning Date
- BMEA 11-04-2025
- ATOM 10-28-2025
- Dividend Yield
- BMEA N/A
- ATOM N/A
- EPS Growth
- BMEA N/A
- ATOM N/A
- EPS
- BMEA N/A
- ATOM N/A
- Revenue
- BMEA N/A
- ATOM $38,000.00
- Revenue This Year
- BMEA N/A
- ATOM N/A
- Revenue Next Year
- BMEA N/A
- ATOM $300.00
- P/E Ratio
- BMEA N/A
- ATOM N/A
- Revenue Growth
- BMEA N/A
- ATOM N/A
- 52 Week Low
- BMEA $1.22
- ATOM $2.48
- 52 Week High
- BMEA $8.99
- ATOM $17.55
- Technical
- Relative Strength Index (RSI)
- BMEA 40.15
- ATOM 34.11
- Support Level
- BMEA $1.22
- ATOM $2.98
- Resistance Level
- BMEA $1.35
- ATOM $3.23
- Average True Range (ATR)
- BMEA 0.10
- ATOM 0.27
- MACD
- BMEA 0.00
- ATOM -0.10
- Stochastic Oscillator
- BMEA 31.16
- ATOM 11.50
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About ATOM Atomera Incorporated
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used transistor types in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, logic and processors, and SRAM.